Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Pioneers: Triple Helix: New Business Models_Open Innovation, Virtual Organizations, Royalty Aggregators, Etc.
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
Industry: Silicon Valley, California
Sagimet Biosciences Inc. (NASDAQ: SGMT)*

Organization & Developments: Sagimet Biosciences

Parents

2024: FDA grants breakthrough status to Sagimet’s denifanstat to treat MASH with fibrosis
2024: Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
2024: Sagimet Biosciences Advances MASH Treatment with Denifanstat_ www.tipranks.com
2024: Sagimet Biosciences announces Phase 2b FASCINATE trial met primary endpoint_ www.tipranks.com
2024: Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
2024: Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
2024: Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat_seekingalpha.com
2024: Sagimet: Additional Upside Possible After Latest NASH Data Release
2024: Sagimet: More Than Just A MASH Drug Development Biotech
2024: UBS says Sagimet stock could steal the MASH spotlight from injectables By Investing.com
2025: Sagimet Biosciences' Denifanstat Should Be Worth More Today_seekingalpha.com
2025: Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development
2025: Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567